Trial Details
Area of Research: Moderate to Severe Plaque Psoriasis
Phase 3

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Brief Summary:

The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in adolescent participants aged 12 to <18 years with moderate to severe plaque psoriasis. This study has two parts. Part A will evaluate the drug levels of BMS-986165 in adolescent participants ages 12 to <18 years to enable selection of 2 dose levels to be studied in Part B. Part B will assess the efficacy and safety of two dose levels in adolescents participants with moderate to severe plaque psoriasis.The long-term extension (LTE) period will observe the long-term safety and tolerability of deucravacitinib in adolescent participants with psoriasis who have completed Parts A or B of the study.

For more information, please contact the recruiting sites directly.
If there is no contact information, please email: The first line of the email MUST contain the NCT # and Site #.

21 locations available.
Related Molecular Pathways
    The safety and efficacy of investigational agents and/or investigational uses or combination of agents approved for other indications have not been established. There is no guarantee that investigational agents or regimens will receive health authority approval or become commercially available in any country for uses under investigation.

    Log In

    Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.

    Don't have an account? Sign Up


    Please enter your email address.

    You will receive a link to create a new password via email.

    Log In


    Create Account

    Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.

    • 8 characters minimum
    • First character cannot be a number
    • Last character cannot be a number